F Fuzkk Atlas of Asia, the Middle East, Canada, Australia and Africa
#123Extended selection 101–300

Binex

South Korea · East Asia

API / CDMO / synthesis

Manufacturing profile

API / CDMO / synthesis

Country: South Korea

Macro-region: East Asia

Selection basis

The company is placed in positions 101–300 as a manufacturer, biotech, specialty-pharma, generics or CDMO company with practical relevance to the existing FUZKK catalog.

The Top 300 is a FUZKK atlas priority rather than a single official revenue table. China, India, Israel, the USA and the European scope are excluded because separate atlases already cover them.

Representative manufacturing and QC chain

  1. 1Route development, raw materials and scale-up
  2. 2Synthesis, bioprocessing or formulation development
  3. 3Purification, filtration, drying or aseptic processing
  4. 4Technology transfer, cleaning and change control
  5. 5HPLC/GC/KF/ICP/LC-MS and method-validation evidence

Relevant FUZKK packages

South Korea: national essential medicines QC packageGlobal API & Biosimilars QC SuiteWorld API Extension QC SuiteFermentation & Antibiotic Intermediates QC SuiteLumex QC Suite

Product/API utilities

—

Lumex — instrumental QC

Method Validation Data Packager

LabEx — laboratory QC

Assay & Impurity HPLC Quality CheckerResidual Solvents GC Quality CheckerWater Content KF Quality CheckerElemental Impurities ICP Quality CheckerLC-MS Confirmation Quality Checker

Medical Devices — equipment and software lifecycle

Process Validation CheckerChange Control Impact CheckerSupplier Evaluation CheckerProduction Record Consistency CheckerCalibration Status CheckerRequirement Traceability CheckerData Integrity Security Checker

Suggested first pilot

  1. Confirm one real product, method or recurring QC review.
  2. Record the instrument, export format and current specification.
  3. Select 3–7 utilities from the map above.
  4. Run a PASS/FAIL sample and agree the expected output.
  5. After user validation, expand to other products and sites.

Mapping boundary

The Top 300 is a FUZKK atlas priority rather than a single official revenue table. China, India, Israel, the USA and the European scope are excluded because separate atlases already cover them.

Methodology